Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-05 06:06 am Purchase | 2025-12-19 | 13D | NextCure, Inc. NXTC | Sofinnova Venture Partners XI, L.P. ("SVP XI") | 222,654 7.100% | 222,654 (New Position) | Filing History |
| 2026-02-17 5:28 pm Purchase | 2025-12-31 | 13G | NextCure, Inc. NXTC | Ikarian Capital, LLC | 363,035 9.990% | 363,035 (New Position) | Filing History |
| 2026-02-17 12:00 pm Purchase | 2025-12-31 | 13G | NextCure, Inc. NXTC | Squadron Master Fund LP | 271,127 9.900% | 97,266 (+55.94%) | Filing History |
| 2026-02-13 5:07 pm Sale | 2025-12-31 | 13G | NextCure, Inc. NXTC | PFIZER INC PFE | 157,646 3.000% | -302,731 (-65.76%) | Filing History |
| 2026-02-12 12:05 pm Purchase | 2025-12-31 | 13G | NextCure, Inc. NXTC | SilverArc Capital Management, LLC | 176,057 5.020% | 176,057 (New Position) | Filing History |
| 2026-01-29 9:33 pm Purchase | 2026-01-22 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 348,607 9.990% | 156,725 (+81.68%) | Filing History |
| 2025-11-14 4:10 pm Purchase | 2025-09-30 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 191,882 7.170% | 191,882 (New Position) | Filing History |
| 2025-10-24 4:37 pm Purchase | 2025-10-21 | 13G | NextCure, Inc. NXTC | Squadron Master Fund LP | 173,861 6.500% | 173,861 (New Position) | Filing History |
| 2025-08-19 9:46 pm Purchase | 2025-06-20 | 13G | NextCure, Inc. NXTC | Simcere Zaiming Inc. | 338,636 12.700% | 338,636 (New Position) | Filing History |
| 2025-05-12 12:54 pm Purchase | 2025-03-31 | 13G | NextCure, Inc. NXTC | CITIGROUP INC C | 100,433 4.300% | 100,433 (New Position) | Filing History |
| 2025-02-14 1:40 pm Sale | 2024-12-31 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 0 0.000% | -208,333 (Position Closed) | Filing History |
| 2024-11-14 6:59 pm Purchase | 2024-09-30 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 208,333 8.900% | 41,628 (+24.97%) | Filing History |
| 2024-11-13 4:06 pm Purchase | 2024-09-30 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 191,883 8.220% | 52,480 (+37.65%) | Filing History |
| 2024-06-27 4:47 pm Purchase | 2024-06-20 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 139,403 5.980% | 139,403 (New Position) | Filing History |
| 2024-04-01 6:34 pm Purchase | 2024-04-01 | 13G | NextCure, Inc. NXTC | Logos Global Management LP | 166,705 7.200% | 166,705 (New Position) | Filing History |
| 2024-03-08 4:34 pm Sale | 2024-03-06 | 13D | NextCure, Inc. NXTC | ORBIMED ADVISORS LLC | 105,668 4.500% | -120,250 (-53.23%) | Filing History |
| 2024-01-19 4:26 pm Sale | 2023-12-31 | 13G | NextCure, Inc. NXTC | Millennium Management LLC | 95,032 4.100% | -25,791 (-21.35%) | Filing History |
| 2023-02-06 3:02 pm Sale | 2022-12-31 | 13G | NextCure, Inc. NXTC | Lilly Asia Ventures Fund III L.P. | 0 0.000% | -142,033 (Position Closed) | Filing History |
| 2023-01-24 4:23 pm Purchase | 2023-01-19 | 13G | NextCure, Inc. NXTC | Millennium Management LLC | 120,824 5.200% | 120,824 (New Position) | Filing History |
| 2022-02-09 12:20 pm Sale | 2021-12-31 | 13G | NextCure, Inc. NXTC | Lilly Asia Ventures Fund III L.P. | 142,033 6.200% | -32,039 (-18.41%) | Filing History |